Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Novo Nordisk Partners with OpenAI to Accelerate Drug Discovery and Transform Healthcare Operations

Fineline Cube Apr 15, 2026
Company Deals

AC Immune and Eli Lilly Amend 2018 Alzheimer’s Partnership to Advance Tau Morphomer Candidates

Fineline Cube Apr 15, 2026
Company Deals

Autobio Diagnostics Expands Global IVD Footprint with Dual Vietnam Partnerships

Fineline Cube Apr 15, 2026
Company Deals

Er-Kim Secures Exclusive CEE Commercial Rights for LOQTORZI Anti-PD-1 Antibody from LEO Pharma

Fineline Cube Apr 15, 2026
Company Deals

UCB Secures EU Approval for Kygevvi as First-Ever Treatment for Ultra-Rare TK2 Deficiency

Fineline Cube Apr 15, 2026
Policy / Regulatory

China’s State Council Unveils Comprehensive Drug Pricing Reforms to Strengthen Market-Oriented Mechanisms and Innovation Incentives

Fineline Cube Apr 15, 2026
Company Drug

Fosun Pharma Advances Dual-Target CAR-T Therapy FKC289 into Clinical Trials for Rare Kidney and Blood Disorders

Fineline Cube Apr 15, 2026
Company Drug

Gan & Lee Pharmaceuticals Doses First Patient in Phase III Trial for Novel Long-Acting Insulin GZR33 in Type 2 Diabetes

Fineline Cube Apr 15, 2026
Company Deals Drug

Novartis Secures Global Rights to PTC Therapeutics’ Huntington’s Disease Treatment PTC518

Fineline Cube Dec 3, 2024

Swiss pharmaceutical giant Novartis (NYSE: NVS) has entered into a global license and collaboration agreement...

Company Deals

UCB Partners with BioRay Biopharmaceutical for Bimzelx Commercial Promotion in China

Fineline Cube Dec 3, 2024

Belgium based UCB (EBR: UCB) is fulfilling its commitment to enhance attention to innovative products...

Company Drug

Minghui Pharmaceutical’s MH004 Ointment Meets Primary Endpoints in Atopic Dermatitis Phase III Study

Fineline Cube Dec 2, 2024

Shanghai-based Minghui Pharmaceutical, a late-stage biopharmaceutical company specializing in immunology and oncology, has announced positive...

Policy / Regulatory

China’s NHC Launches Pilot Plan to Expand Wholly Foreign-Owned Hospital Sector

Fineline Cube Dec 2, 2024

The National Health Commission (NHC) has released the “Pilot Work Plan for Expanding the Wholly...

Company Drug

Hua Medicine’s Second-Generation GKA HM-002-1005 Completes Phase Ia Study in the US

Fineline Cube Dec 2, 2024

China-based Hua Medicine (HKG: 2552) has announced the successful completion of a Phase Ia study...

Company Drug

Shanghai MicuRx’s MRX-4/Contezolid Meets Primary Endpoint in Phase III cSSTI Study

Fineline Cube Dec 2, 2024

Shanghai MicuRx Pharmaceutical Co., Ltd. (SHA: 688373) has announced that its Phase III study for...

Company Deals

CBC Group and Mubadala Acquire UCB’s Neurology and Allergy Business in China for $680 Million

Fineline Cube Dec 2, 2024

Singapore-based healthcare private equity firm CBC Group and Mubadala Investment Company, a global investment company...

Company Drug

Simcere Zaiming Launches Phase III Trial for SERD Inhibitor SIM0270 in Breast Cancer

Fineline Cube Dec 2, 2024

Simcere Pharmaceutical Group Limited’s (HKG: 2096) subsidiary, Simcere Zaiming, has announced the initiation of a...

Company Drug

Hua Medicine’s SENSITIZE Study Illuminates Dorzagliatin’s β-Cell Glucose Sensitivity Mechanism

Fineline Cube Dec 2, 2024

China-based innovative drug developer Hua Medicine (HKG: 2552), with operations in the US and Hong...

Company Deals

Sunflower Pharmaceutical Group to Establish Joint Lab with Peking University for Bacterial Enzyme Research

Fineline Cube Dec 2, 2024

China-based Sunflower Pharmaceutical Group Co., Ltd. (SHE: 002737) is poised to establish a joint laboratory...

Company Drug

Simcere Pharmaceutical’s Edaravone and Borneol Sublingual Tablets Approved for AIS Treatment in China

Fineline Cube Dec 2, 2024

China-based Simcere Pharmaceutical Group Limited (HKG: 2096) has announced receiving marketing approval from the National...

Company Drug

Shanghai Pharmaceuticals Concludes Phase II Study for I037 in Acute Ischemic Stroke

Fineline Cube Dec 2, 2024

Shanghai Pharmaceuticals Holding Co., Ltd. (HKG: 2607, SHA: 601607) has announced the completion of data...

Company Deals

Affinity (Shanghai) Secures Over RMB 400 Million in Series B2 Financing to Advance Oncology Drugs

Fineline Cube Dec 2, 2024

Affinity (Shanghai), the parent company of Shanghai Affinity Biopharmaceutical Co., Ltd., has reportedly raised upwards...

Company Deals Hospital

Abogen Biosciences and Ruijin Hospital Launch Ruijin Abogen Nucleic Acid Drug Research Institute

Fineline Cube Dec 2, 2024

China-based nucleic acid drug developer Suzhou Abogen Biosciences and Ruijin Hospital, a comprehensive Class 3A...

Company Drug

Henlius Biotech Initiates US Commercial Supply of Hanquyou, Biosimilar to Herceptin

Fineline Cube Dec 2, 2024

Shanghai Henlius Biotech, Inc. (HKG: 2696) has announced the initiation of commercial supply of its...

Company Drug

ImmuneOnco Biopharmaceuticals Receives NMPA Approval for Lupus Nephritis Phase II Study

Fineline Cube Dec 2, 2024

ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (HKG: 1541), a China-based biopharmaceutical company, has announced receiving approval from...

Company Drug

Healthgen Biotechnology’s Plant-Made Albumin Breakthrough: A Milestone in Serum Therapy

Fineline Cube Dec 1, 2024

On November 30th, Healthgen Biotechnology Corp. announced a significant research outcome at the 9th Pharmaceutical...

Company

Shanghai Cell Therapy Group’s Second Attempt at HK IPO Receives Green Light from CICC and CCB International

Fineline Cube Dec 1, 2024

Shanghai Cell Therapy Group Co., Ltd., a leading player in China’s cellular medical health sector,...

Company

Nanjing Leads Biolabs Commences IPO Process with Focus on Innovative Therapies

Fineline Cube Nov 30, 2024

Nanjing Leads Biolabs Co., Ltd., a clinical-stage biopharmaceutical company focused on developing innovative therapies for...

Company Drug

XellSmart Bio-Pharmaceutical Achieves Milestone with First Patient Enrollment in Global iPSC Clinical Study for ALS

Fineline Cube Nov 30, 2024

XellSmart Bio-Pharmaceutical (Suzhou) Co., Ltd., in collaboration with Shanghai East Hospital (Tongji University Affiliated East...

Posts pagination

1 … 241 242 243 … 651

Recent updates

  • Novo Nordisk Partners with OpenAI to Accelerate Drug Discovery and Transform Healthcare Operations
  • Fosun Pharma Advances Dual-Target CAR-T Therapy FKC289 into Clinical Trials for Rare Kidney and Blood Disorders
  • China’s State Council Unveils Comprehensive Drug Pricing Reforms to Strengthen Market-Oriented Mechanisms and Innovation Incentives
  • Gan & Lee Pharmaceuticals Doses First Patient in Phase III Trial for Novel Long-Acting Insulin GZR33 in Type 2 Diabetes
  • AC Immune and Eli Lilly Amend 2018 Alzheimer’s Partnership to Advance Tau Morphomer Candidates
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Novo Nordisk Partners with OpenAI to Accelerate Drug Discovery and Transform Healthcare Operations

Company Drug

Fosun Pharma Advances Dual-Target CAR-T Therapy FKC289 into Clinical Trials for Rare Kidney and Blood Disorders

Policy / Regulatory

China’s State Council Unveils Comprehensive Drug Pricing Reforms to Strengthen Market-Oriented Mechanisms and Innovation Incentives

Company Drug

Gan & Lee Pharmaceuticals Doses First Patient in Phase III Trial for Novel Long-Acting Insulin GZR33 in Type 2 Diabetes

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.